Sentinel Lymph Node Biopsy (SLNB)

Sentinel lymph node biopsy is a minimally invasive staging procedure that identifies and removes the first lymph node(s) to which cancer cells are most likely to spread. The 'sentinel' node is the gateway node that filters lymphatic fluid draining from the tumor site. A radioactive tracer and/or blue dye is injected around the tumor, travels through lymphatic channels, and concentrates in the sentinel node(s). The surgeon uses a handheld gamma probe and visual guidance to locate and remove typically 1-3 sentinel nodes. If these nodes are negative for cancer, there is >95% probability that remaining lymph nodes are also negative, avoiding the need for full lymph node dissection.

SLNB removes only 1-3 sentinel nodes through a small incision with 30-60 minute procedure time, same-day discharge, and 5-7% lymphedema risk. Full axillary lymph node dissection (ALND) removes 10-20 or more nodes through a larger incision, requires 1-2 hour surgery, overnight stay, and carries 20-30% lymphedema risk. Per NSABP B-32 trial with 8-year follow-up, SLNB provides equivalent staging accuracy to ALND with significantly reduced morbidity. SLNB has replaced ALND as the standard of care for clinically node-negative breast cancer and melanoma staging.

Three main techniques exist: (1) Radiotracer-guided using Technetium-99m sulfur colloid with gamma probe detection (97-99% identification rate); (2) Blue dye only using isosulfan blue, methylene blue, or patent blue V (higher 10-15% false-negative rate); (3) Dual-tracer technique combining radiotracer plus blue dye (gold standard with lowest 5.5-6.7% false-negative rate and >98% identification rate per ASCO/SSO guidelines). A newer option is ICG (indocyanine green) fluorescence with near-infrared imaging, offering no radiation exposure and real-time visualization. Thai hospitals primarily use the dual-tracer technique for optimal accuracy.

Ideal candidates include: Breast cancer patients with clinically node-negative (cN0) invasive cancer, T1-T2 tumors; DCIS undergoing mastectomy (20-25% upstaging risk); Melanoma patients with Breslow thickness >=0.8mm or ulcerated tumors <0.8mm; Early-stage head/neck squamous cell carcinoma with cN0 neck. Contraindications include: palpable lymphadenopathy or imaging-confirmed nodal metastasis; biopsy-proven nodal metastasis; inflammatory breast cancer; prior complete axillary dissection; severe allergy to tracer agents. Prior neoadjuvant chemotherapy is now a relative (not absolute) contraindication with targeted axillary dissection protocols.

Based on SOUND and INSEMA trial data, SLNB may be safely omitted in select low-risk breast cancer patients meeting ALL criteria: age >=50 years, postmenopausal; tumor size <=2cm (cT1); grade 1-2 (well to moderately differentiated); HR-positive, HER2-negative; negative axillary ultrasound; planned breast-conserving therapy with whole breast radiation; planned adjuvant endocrine therapy. In this select population, SLNB does not change treatment decisions or improve oncologic outcomes. This represents a significant shift in practice, reducing unnecessary surgery for appropriate candidates.

Positive SLNB triggers multidisciplinary tumor board discussion. For breast cancer with 1-2 positive nodes undergoing breast-conserving surgery with radiation, ALND may be omitted per ACOSOG Z0011 trial. For >=3 positive nodes, ALND is typically recommended with regional nodal irradiation. For melanoma, completion lymph node dissection (CLND) was historically standard but is now controversial per MSLT-II trial; observation with ultrasound surveillance is an accepted alternative with adjuvant immunotherapy (pembrolizumab, nivolumab) or targeted therapy (BRAF/MEK inhibitors) for eligible patients.

False-negative rates vary by technique and cancer type: Dual-tracer technique achieves lowest rate of 5.5-6.7% (gold standard). Blue dye alone has higher 10-15% false-negative rate. For breast cancer overall: 5-10% per meta-analysis. For melanoma: varies by location - head/neck 12%, trunk 6%, extremities 3% (per MSLT-I trial). Factors increasing false-negative risk include: <3 sentinel nodes harvested, prior neoadjuvant chemotherapy, lymphovascular invasion, large/multicentric tumors. Regional recurrence after negative SLNB occurs in <5% at 8-year follow-up per NSABP B-32 trial.

Recovery is significantly faster than ALND: Days 1-3: Rest, mild pain managed with acetaminophen/NSAIDs, limited arm use, blue discoloration fades (if dye used). Days 4-7: Return to light activities and desk work, driving permitted. Weeks 1-2: Resume most normal activities, await final pathology (3-5 days), follow-up appointment. Weeks 2-4: Full activity including exercise. No lifting >5 lbs first week, >10 lbs until 2 weeks. Physical therapy rarely needed unless lymphedema develops. Numbness in axilla may persist but typically improves over 6-12 months.

Thailand offers 60-70% cost savings: Standalone SLNB: Thailand $2,000-$5,000 vs US $5,000-$15,000. SLNB + Lumpectomy: Thailand $8,000-$15,000 vs US $25,000-$50,000. SLNB + Mastectomy: Thailand $12,000-$20,000 vs US $35,000-$80,000. Lymphoscintigraphy: Thailand $300-$500 vs US $1,000-$2,500. Pathology (frozen + permanent): typically included in Thailand, $500-$1,500 additional in US. Prices verified January 2026; confirm current rates with hospitals.

Minimum stays vary by procedure: Standalone SLNB: 2-3 days minimum (pathology results typically 3-5 business days). Combined with lumpectomy: 5-7 days. Combined with mastectomy: 7-10 days. Plan to remain until final pathology available and initial treatment plan discussed. Air travel safe 2-3 days after standalone SLNB, 5-7 days after combined procedures. Use compression stockings for flights >4 hours, ambulate hourly, avoid carrying heavy luggage on affected side.

Five JCI-accredited hospitals offer comprehensive SLNB services (verified January 2026): Bumrungrad International Hospital - Horizon Cancer Center with full oncology services, nuclear medicine for lymphoscintigraphy, multidisciplinary tumor boards. Bangkok Hospital (Bangkok Cancer Hospital) - Comprehensive cancer center with AI-enhanced imaging, weekly tumor boards. Samitivej Hospital - Breast cancer program with SLNB, international patient services. MedPark Hospital - Modern oncology facility with international patient focus. Vejthani Hospital - Cancer center with breast surgery program. All have nuclear medicine departments, gamma probe equipment, and frozen section pathology capabilities.

Essential documents include: Complete operative report with sentinel node count, location, and tracer technique used. Final pathology report with immunohistochemistry results (cytokeratin stains for micrometastasis). Imaging studies on disc/USB (lymphoscintigraphy, any staging scans). Discharge summary with medication list. Follow-up recommendations and timeline. Contact information for Thai medical team (most hospitals offer 24/7 international line). Adjuvant treatment recommendations if SLNB positive. Coordinate with home oncologist for ongoing care including surveillance protocol or additional treatment planning.